UK Markets closed
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • FTSE 250

    19,462.71
    +66.37 (+0.34%)
     
  • AIM

    1,039.01
    +0.98 (+0.09%)
     
  • GBP/EUR

    1.1125
    -0.0086 (-0.77%)
     
  • GBP/USD

    1.3314
    -0.0042 (-0.3169%)
     
  • BTC-GBP

    13,603.93
    +251.02 (+1.88%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • DOW

    29,910.37
    +37.90 (+0.13%)
     
  • CRUDE OIL

    45.53
    -0.18 (-0.39%)
     
  • GOLD FUTURES

    1,788.10
    -23.10 (-1.28%)
     
  • NIKKEI 225

    26,644.71
    +107.40 (+0.40%)
     
  • HANG SENG

    26,894.68
    +75.23 (+0.28%)
     
  • DAX

    13,335.68
    +49.11 (+0.37%)
     
  • CAC 40

    5,598.18
    +31.39 (+0.56%)
     

Abivax Receives 'Best Technology Award' at the European Mediscience Awards 2020

·6-min read

DGAP-News: ABIVAX / Key word(s): Miscellaneous
16.11.2020 / 18:30
The issuer is solely responsible for the content of this announcement.

Abivax Receives "Best Technology Award" at the European Mediscience Awards 2020

PARIS, November 16, 2020 - xx:00 a.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced today that it received the "Best Technology Award" at the European Mediscience Awards 2020. The Award recognizes solutions which are highly innovative, well-funded, and capable of significant commercial success and, out of the four shortlisted companies, Abivax's technology was selected as the most deserving by this year's Mediscience Voting Panel.

Abivax received the award for ABX464, an innovative drug candidate with a novel, unique mechanism of action derived from the Company's chemical library of over 2,200 small molecules. With its antiviral and anti-inflammatory effect as well as tissue repair properties that have been demonstrated in several pre-clinical as well as clinical studies, ABX464 has the potential to treat several severe, acute and chronic inflammatory diseases. ABX464's clinical late-stage development programs currently focus on chronic inflammatory bowel diseases, particularly ulcerative colitis and Crohn's disease. ABX464 is also being tested in rheumatoid arthritis and, more recently, in Covid-19 to evaluate its potential to prevent hyper-inflammation and to inhibit the replication of the SARS-CoV-2 virus in high-risk patients. The Company is constantly exploring further indications where ABX464 might be beneficial for patients.

"We are proud and feel honored to receive the "Best Technology Award" and I would like to thank the entire Abivax team for their efforts and commitment. This distinction once again validates the promising potential of our drug candidate, ABX464. The recently published two-year data of the Phase 2a maintenance study in ulcerative colitis confirmed its good safety profile along with promising short- and long-term clinical efficacy," said Prof. Hartmut Ehrlich, M.D., CEO of Abivax. "Abivax's lead molecule has the potential to become the first in a novel class of oral and easy administrable drugs that could be a game changer in the treatment of chronic inflammatory diseases, a huge market with a high unmet medical need. We look forward to further exploring and developing the full potential of ABX464 for the benefit of all patients in need of novel therapeutic management options."

About ABX464's Mechanism of Action
ABX464 is a highly differentiated oral drug candidate, with a novel mechanism of action based on the upregulation of a single microRNA (miR-124) with potent anti-inflammatory properties. ABX464 was shown to exert its anti-inflammatory effects through binding to the cap binding complex (CBC), which sits at the 5' end of every RNA molecule in the cell. By binding to the CBC, ABX464 reinforces the biological functions of CBC in cellular RNA biogenesis. Specifically, ABX464 enhances the selective splicing of a single long non-coding RNA to generate the anti-inflammatory microRNA, miR-124, which downregulates pro-inflammatory cytokines and chemokines like TNF-α, IL-6 and MCP-1, thereby "putting a brake" on inflammation and suggesting broad potential as a novel anti-inflammatory therapeutic agent. A seven- to ten-fold increase in miRNA-124 levels was observed in colorectal biopsies of UC patients treated with ABX464. ABX464 does not impact the splicing of cellular genes.

About the European Mediscience Awards 2020
The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognize success. Each year sees the attendance of over 500 public and private European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. This year, in its 19th edition, the European Mediscience Awards is hosted as a digital event.

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with autoimmune diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.
More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.


Contacts

 

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.


16.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63


Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254


Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22


Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24


Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84


Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017


Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63


Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254


Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22


Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24


Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84


Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

show this
show this